Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357335 | 0.89 | PKM (0.68) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL1024088 | 0.87 | HTT (0.62) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL6756073 | 0.86 | HSP90AA1 (0.64) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL10743936 | 0.85 | HTT (0.60) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL8772648 | 0.85 | HSP90AA1 (0.57) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL5465657 | 0.85 | HSP90AA1 (0.57) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL27564987 | 0.84 | ALDH1A1 (0.54) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL8252051 | 0.84 | HTT (0.59) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL9763047 | 0.83 | HSP90AA1 (0.65) | HTTALDH1A1HPGDHSP90AB1HSP90AA1 | |
| SCHEMBL2991009 | 0.83 | CA12 (0.58) | HTTALDH1A1HPGDPOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1582250-B2 | Absorbent with improved oxidation resistance and process for deacidifying fluid fluxes | BASF SE (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-1582250-B1 | Absorbent with improved oxidation resistance and process for deacidifying fluid fluxes | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| EP-1582250-A2 | Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | HTT 384/4885ALDH1A1 1197/4885HPGD 3387/4885 |
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | HTT 2386/4885ALDH1A1 151/4885HPGD 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.